1 / 17

Cattle Vaccine and DIVA Development

Cattle Vaccine and DIVA Development. Martin Vordermeier 3 rd October 2013, ZSL London. Supporting DEFRA policy on cattle TB vaccination:.

rianne
Download Presentation

Cattle Vaccine and DIVA Development

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cattle Vaccine and DIVADevelopment Martin Vordermeier 3rd October 2013, ZSL London

  2. Supporting DEFRA policy on cattle TB vaccination: • Towards field trials and licensing of BCG, regulatory aspects: Efficacy studies (within group) and GLP safety studies (as sponsors and Defra project managers) • Development of associated DIVA test(s) that would work alongside BCG vaccination • Looking further ahead approaches: • Vaccines/vaccination strategies that improve on BCG such as subunit vaccines that supplement/enhance BCG efficacy • Vaccines that do not sensitise tuberculin skin test reactions so that one could continue with existing test and slaughter strategies alongside vaccination • Cross-cutting objective: • Protective biomarker studies to accelerate vaccine development

  3. BCG is a proven technology Live attenuated Mycobacterium bovis Attenuated in cattle since 1912 Used in humans since 1927 Safe in a wide range of species Cheap Recommended by WHO for humans Different vaccine strains available: we use BCG Danish SSI as this is licensed in UK for humans Variable efficacy in humans and cattle and compromises tuberculin-based diagnosis

  4. Experimental approaches to test TB vaccines in cattle Model Advantages Disadvantages Experimental challenge: Low dose intratracheal model ‘Few’ animals required (n <10-12/group) Still relatively high dose: Immune system may be overwhelmed, vaccine effect may be an under-estimate Short duration (3-4 months) ‘Field experiment’: In contact transmission Natural route and infective dose High transmission rates or large group sizes required Long in-contact period (12 months) Field trial Real-life situation Very large numbers required Long and expensive (years) 4

  5. BCG Danish vaccination experiments in cattle after intra-tracheal infection conducted at AHVLA/IAH: Effective vaccine , 1-year duration of immunity N N N N 1-year DOI 2-years DOI 1 year M. bovis BCG 2 years M. bovis BCG

  6. Protection offered by BCG SSI Danish vaccination:Equal protection of young (neonatal/< 6 weeks) and older calves

  7. Ethiopian ‘Natural transmission model’ • Evaluation of the efficacy of BCG in bovine neonates under natural transmission in Ethiopia • Vaccinated and control calves in contact with infected cows (12 - 22 months)

  8. TB Unvaccinated sentinel Vaccinated sentinel Reactor (TB) TB TB TB TB TB TB TB TB

  9. ‘Natural Transmission’ study: Main Findings • 69 % of vaccinated animals were fully protected from infection having no signs of visible lesions and being culture-negative compared to 21 % of cattle in the control group. This equates to a level of protection of 61 % (Ameni et al. 2010). • When the condemnation rate at meat inspection was used as additional read-out system, 73 % of the control cows would have been condemned compared to 23 % of the vaccinated (= 68 % protection). • This study suggested that duration of immunity may be longer in the field than the minimum of one year demonstrated through the experimental vaccination and challenge experiments (> 22 months) • Effectiveness of cattle vaccination in GB field conditions is currently unknown.

  10. Safety studies in cattle • Two safety studies completed • Neonatal cattle • Detected no spread beyond immediate draining of lymph nodes in a minority of animals • No shedding in faeces or saliva • Pregnant cattle • Detected no spread beyond immediate draining of lymph nodes in a minority of cows • No shedding in faeces, saliva, colostrum or milk Two more GLP safety studies ( ‘animal phase’ to start October 2013): • Meat safety: Kinetics of dissemination in calves • Milk safety: Vaccination of lactating cattle

  11. Summary BCG • BCG strains tested (Pasteur and Danish) give equivalent protection): Danish chosen because licensed in UK for humans • Neonatal BCG vaccination as good as vaccinating older animals • BCG protected cattle in experimental challenge studies AND better in field exposure study • BCG vaccination reduces the progression, severity of TB and could reduce transmission between animals • Duration of immunity: at least 1 year (annual re-vaccination), but field experiment suggested may last longer • Skin test sensitisation is reduced from 80% to 8% between 6-9 months post BCG vaccination so DIVA test required, see second part of talk • Need for field trials to move forward, design and preparatory laboratory studies are in progress • Could be a useful tool, but not perfect - will still need other TB control measures

  12. Differential Immune-Diagnosis Vaccine or cross-reactive pathogen Blood test detects response to components only recognised in TB TB

  13. An effective DIVA test is now available BCG primes for tuberculin reactivity, so vaccination based on BCG would need to be accompanied by a DIVA test DIVA antigens Genes missing from BCG ESAT-6 CFP-10 Genes expressed by BCG but not secreted Rv3615c

  14. Definitions: • Sensitivity – Proportion of true-positives (infected individuals correctly identified) • Specificity – Proportion of true negatives (non-infected individuals correctly identified) OR: probability of test to correctly identify patients who are known NOT to have the disease:

  15. Interferon gamma DIVA test – Validation (IFN-gamma test) • DIVA can be used seriallyor as a stand-alone test • Limited numbers of vaccinated cattle, data shown are serially testing results Compared to PPD-B minus A in the field animals cohorts SE in field = 0.93-0.95, SPE = 0.97-0.98 15

  16. Test systems available for DIVA: • Interferon-gamma release assays (IGRA) based on e.g. Bovigam assay • DIVA based on skin test 16

  17. National and International Network • Jenner Institute, Oxford • IAH, Compton • Roslin Institute, Edinburgh • AFBI, Stormont, NI • University of Surrey, Guildford • AgResearch, Palmerston North, New Zealand • McMaster, Toronto, Canada • NADC, USDA, Ames, USA • Helmholtz Centre, Braunschweig, Germany • Infectious Diseases Research Institute (IDRI), Seattle, USA • INRA, Tours, France • University of Zuerich, Switzerland • Armauer Hansen Research Institute, Ethiopia • UNAM, Mexico City, Mexico • CRESA, Barcelona, Catalonia, Spain • EU-RL, Madrid, Spain • CVL-Lelystad, Lelystad, the Netherlands • Prionics, Schlieren, Switzerland • Lionex Ltd, Braunschweig • SSI, Copenhagen • ID-Vet, Montpellier, France Funded by Defra (UK), EU, Wellcome Trust, TRANSVAC M Vordermeier is a Jenner Investigator

More Related